Articles from Bifrost Biosystems

Bifrost Biosystems today announced that it has secured a commercial supply agreement with Illumina enabling integration of Illumina’s industry-standard sequencing-by-synthesis (SBS) chemistry into its optical pooled screening (OPS) platform slated to be commercially available in early 2027. OPS is a technology to link complex cellular phenotypes to the responsible genetic perturbation cost-effectively and at scale.

Bifrost Biosystems, a pioneer in Optical Pooled Screening (OPS) technologies, today announced the signing of an exclusive license agreement with the Broad Institute of MIT and Harvard. Under the license agreement, Bifrost gains access to a portfolio of intellectual property related to OPS technology and techniques developed in the laboratory of Paul Blainey, PhD, Core Institute Member at the Broad Institute and Professor in the Department of Biological Engineering at MIT. The license from the Broad includes key OPS methods that enhance Bifrost’s leadership position in the nascent functional multi-omics sector.

Bifrost Biosystems, a pioneer in Optical Pooled Screening (OPS) technologies, today announced the appointment of experienced life sciences industry executive, Jonas Jarvius, PhD, as Chief Executive Officer, President and Director. He brings to Bifrost over 15 years of C-level executive experience from both private and public companies translating innovative technologies into commercial products that impact human health outcomes.

Bifrost Biosystems announced today its launch with a vision to power efficient drug discovery through its novel automated Optical Pooled Screening (OPS) platform. The Bifrost OPS platform uniquely integrates rich, image-based, single-cell profiling data with genome-wide CRISPR perturbations. Through advanced software analysis and machine learning/artificial intelligence algorithms, the platform provides actionable, high-quality information to direct next steps in the discovery process.